EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Boudicca will support and advise Adial on its companion diagnostic genetic test to ensure compliance with FDA guidelines'
Portfolio Pulse from Benzinga Newsdesk
Adial Pharmaceuticals has announced that Boudicca will support and advise the company on its companion diagnostic genetic test to ensure compliance with FDA guidelines.
August 13, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adial Pharmaceuticals has partnered with Boudicca to ensure FDA compliance for its companion diagnostic genetic test.
The partnership with Boudicca to ensure FDA compliance is a positive development for Adial Pharmaceuticals, potentially leading to smoother regulatory approval processes and enhancing investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100